Study of G-202 (Mipsagargin) as Second-Line Therapy Following Sorafenib in Hepatocellular Carcinoma; G-202-003

Press/Media: Press / Media

PeriodOct 2 2018

Media coverage

1

Media coverage

  • TitleStudy of G-202 (Mipsagargin) as Second-Line Therapy Following Sorafenib in Hepatocellular Carcinoma; G-202-003
    Media name/outletClinical Trials.gov
    CountryUnited States
    Date10/2/18
    PersonsDevalingam Mahalingam